News
- New Data Opens Potential for Patient Stratification for CriPec® Nanomedicines in Cancer and Other Indications via Non- Invasive Imaging 4 May 2022
- Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms 6 January 2021
- Cristal Therapeutics announces a publication in ‘Chemical Science’ on CliCr® technology platform, comprising a new class of superior copper free click reagents for conjugation of small molecules, biologics, nanoparticles and other moieties 29 September 2020
- Cristal Therapeutics Awarded Horizon 2020 Grant to Further Develop the CriPec® Nanomedicine Platform 2 July 2020
- Cristal Therapeutics Publishes Positive Data on its CriPec® Nanomedicine Technology in Small 11 May 2020
- Cristal Therapeutics appoints Dr Werner Cautreels as a new Director and Board Chairman and Andre Verwei as Chief Financial Officer 1 August 2019
- Cristal Therapeutics to present data at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting on lead clinical candidate CPC634 in patients with solid tumors 17 May 2019
- Dr. Axel Mescheder appointed CEO of Cristal Therapeutics as focus intensifies on proprietary oncology nanomedicine pipeline 1 November 2018
- Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer 24 October 2018
- Cristal Therapeutics awarded €2.5 million Horizon 2020 grant to advance its CriPec®-docetaxel through Phase 2 trials 28 November 2017
- Cristal Therapeutics progresses nanomedicine CriPec®-docetaxel to phase 1b development in patients with solid tumours 1 November 2017
- Dr. Istvan Udvaros joins Cristal Therapeutics as New Chief Medical Officer 24 October 2017
- Cristal Therapeutics further strengthens its Scientific Advisory Board with appointment of Dr. Paul Lammers 9 August 2017
- Cristal Therapeutics raises €12.8 million in new financing round to advance novel medicines against cancer using its CriPec® nanotech platform 19 January 2017
- Cristal Therapeutics and iTeos Therapeutics announce strategic partnership for the development of immuno-oncology therapeutic candidates using Cristal’s CriPec® nanotech platform 6 December 2016
- Cristal Therapeutics announces appointment of Edwin Klumper as Chief Medical Officer 29 April 2016
- Cristal Therapeutics starts clinical phase I trial with nanomedicine CriPec® docetaxel in patients with solid tumours 29 September 2015
- Cristal Therapeutics Announces Collaboration With PX Biosolutions to Develop CriVac® Based vaccines 14 July 2015
- Cristal Therapeutics’ proprietary CriPec® nanomedicine platform and promising preclinical data highlighted in three recent publications 22 June 2015
- Cristal Therapeutics announces formation of Scientific Advisory Board 22 May 2015
- Cristal Therapeutics announces appointment of Jeroen Tonnaer as Chief Business Officer 21 April 2015
- €6 million in new capital and new CEO 16 December 2014
- Cristal Therapeutics and Enabling Technologies 24 March 2014
- Cristal Therapeutics raises additional funding for its lead product CriPec® docetaxel 1 July 2013
- Nedermaas Ventures en Innovatiefonds investeren in Cristal Delivery 29 May 2013
- Cristal Delivery wint Utrechtse Ster 2012 31 October 2012
- Nanomedicijn bedrijf Cristal Delivery verhoogt de therapeutische waarde van geneesmiddelen 14 June 2011
© Cristal Therapeutics
Oxfordlaan 55
6229 EV Maastricht
Netherlands
Pages
- CriPec® technology platform
- Home
- News
- Overview
- Pipeline
- About us
- CliCr® copper free click chemistry reagent
- Events
- Management team
- Oncology programs
- Inflammation programs
- Programs
- Publications
- Supervisory board
- Scientific advisory board
- Technology
- Investors
- Partnering
- Media Centre
- Careers
- Contact Us
- Disclaimer